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Exposure to stress or traumatic events can lead to the development of depression
and anxiety disorders. In addition to the debilitating consequences on mental health,
patients with psychiatric disorders also suffer from autonomic imbalance, making them
susceptible to a variety of medical disorders. Emerging evidence utilizing spectral analysis
of heart rate variability (HRV), a reliable non-invasive measure of cardiovascular autonomic
regulation, indicates that patients with depression and various anxiety disorders (i.e., panic,
social, generalized anxiety disorders, and post traumatic stress disorder) are characterized
by decreased HRV. Social stressors in rodents are ethologically relevant experimental
stressors that recapitulate many of the dysfunctional behavioral and physiological changes
that occur in psychological disorders. In this review, evidence from clinical studies
and preclinical stress models identify putative biomarkers capable of precipitating the
comorbidity between disorders of the mind and autonomic dysfunction. Speciﬁcally, the
role of corticotropin releasing factor, neuropeptideY and inﬂammation are investigated.The
impetus for this review is to highlight stress-related biomarkers that may prove critical in
the development of autonomic imbalance in stress -related psychiatric disorders.
Keywords: social defeat, corticotropin releasing factor, neuropeptideY, inflammation, post traumatic stress disorder,
anxiety, depression, heart rate variability
Stress that stems from one’s social environment is the most com-
mon formof stress encountered by people and is perceived asmore
intense than other types of stressors (Almeida, 2005). Socially
stressful events are well recognized as contributing to the patho-
genesis of depression, anxiety and posttraumatic stress disorder
(PTSD; Kessler, 1997; Kendler et al., 1999; Javidi and Yadollahie,
2012). In addition to the debilitating consequences these psy-
chiatric disorders have on mental health, they are also strongly
associated with cardiovascular disease (CVD). As a result, psychi-
atric disorders signiﬁcantly increase the risk of cardiac morbidity
and mortality (Anda et al., 1993; Barefoot et al., 1996; Penninx
et al., 2001; Rugulies, 2002; Surtees et al., 2008). Despite the clinical
association between stress-related psychiatric disorders and CVD,
little is understood regarding the pathophysiology or biomarkers
underlying these comorbid disorders.
AUTONOMIC IMBALANCE IN PATIENTS WITH PSYCHIATRIC
DISORDERS: RELEVANCE TO HEART DISEASE
One physiological change observed in patients with psychiatric
disorders thought to contribute to increased CVD risk is dys-
function within the autonomic nervous system as evidenced by
changes in heart rate variability (HRV). HRV reveals beat-to-beat
changes in heart rate measured by the electrocardiogram. Vari-
ability within the heart rate is regulated by the sympathetic nerves,
which accelerate heart rate and the parasympathetic (vagus) nerve,
which slows it. Therefore, HRV provides a non-invasive measure
of the balance between the sympathetic and parasympathetic ner-
vous system. Healthy cardiac activity is characterized by a high
degree of parasympathetic input and thus increased variability,
protecting the heart against adverse cardiac events such as heart
failure and myocardial infarction (Bigger et al., 1988; Hughes and
Stoney, 2000; Carney et al., 2001). Alternatively, reductions in
HRV that reﬂect increased sympathetic tone increase the risk
of cardiac arrhythmias and sudden cardiac death (Verrier and
Lown, 1982; La Rovere et al., 2003). Spectral analysis of HRV
has revealed that increased low frequency (LF) measure of HRV
and decreased high frequency (HF) reﬂect enhanced sympathetic
and decreased parasympathetic activity, resulting in a marked
increase in the LF/HF ratio (Pagani et al., 1986; Berntson et al.,
1997; Ramaekers et al., 2002). Importantly, patients suffering from
stress-related psychiatric disorders also exhibit autonomic dis-
turbances. Major depression, generalized anxiety disorders and
PTSD have all been associated with reductions in HRV (Udupa
et al., 2007; Kemp et al., 2010; Pittig et al., 2013) and suffering
from two of these disorders concurrently is reported to produce
a further reduction in HRV (Chang et al., 2013; Minassian et al.,
2014). A shift in HRV of this manner predicts life-threatening
cardiac arrhythmias (Huikuri et al., 2009) and in patients lacking
preexisting CVD, stress-related disorders such as depression and
anxiety are associated with signiﬁcantly increased risk of adverse
cardiac events (Barefoot et al., 1996; Carney et al., 2001). While
this association is clearly documented, the molecular systems or
biomarkers capable of generating both stress-related psychiatric
disorders and CVD are not deﬁned, making treatment challeng-
ing. Preclinical models of social stress have provided invaluable
clues as to which biological markers may be involved in the
pathogenesis of these comorbid diseases and will be the focus of
this review.
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SOCIAL STRESS-INDUCED DYSFUNCTION IN RODENTS:
RELEVANCE TO HUMAN PSYCHIATRIC AND CVD
COMORBIDITY
Stress is a common risk factor for both CVD and psychiatric dis-
orders. Therefore, identifying stress-sensitive systems thatmediate
cardiovascular and behavioral/emotional responses could shed
light on the shared pathophysiology that links these comorbid
disorders. Two reliable ethologically relevant animal model of
social stress have proven particularly useful for studying this link.
One is the resident-intruder paradigm of social defeat (Miczek,
1979; Sgoifo et al., 2014). This model involves subjecting a male
rat (intruder) to aggressive threats from a larger, unfamiliar male
rat (resident) by placing it in the resident’s home cage for a
short period of time. In the acute sense (minutes to hours)
social defeat produces robust sympathetic activation eliciting 30
times the number of arrhythmias (ventricular premature beats) as
compared to other non-social stressors such as restraint or foot
shock (Sgoifo et al., 1999). Social defeat also produces vagal with-
drawal, tachycardia, hypertension, hyperthermia, elevated plasma
catecholamines, and increased activation of the hypothalamic-
pituitary-adrenal axis (Tornatzky and Miczek, 1993, 1994; Sgoifo
et al., 1999; Bhatnagar et al., 2006;Woodet al., 2010). Another valid
model is social isolation in the socially monogamous prairie voles.
This model involves separating a prairie vole from its opposite-
sex partner and is well characterized as producing long-term
cardiovascular dysfunction within 2–4 weeks. Under resting con-
ditions, isolated prairie voles exhibit elevated heart rate, decreased
HRV (Grippo et al., 2007), and a pronounced increase in cir-
culating corticosterone and adrenal weights (Bosch et al., 2009).
The robust activation of the sympathetic nervous system and
the HPA axis during social defeat and social isolation are simi-
lar to those observed in humans in response to the Trier Social
Stress Test, an experimental model of social stress in humans
(Hellhammer and Schubert, 2012).
Acute stress responses are adaptive in helping the individ-
ual cope with the stressor, however, if unabated in the face
of chronic stress this can lead to pathological changes. There-
fore, social defeat in rodents and social isolation in prairie voles
have behavioral and physiological consequences that are rele-
vant to human pathologies. Cardiovascular telemetry allows for
detailed 24 h cardiac monitoring in unrestrained animals and
has been critical in establishing cardiovascular repercussions to
stress, allowing for direct comparison to humans. From a phys-
iological perspective, social defeat renders rats with disruption
of the circadian rhythm for heart rate and core temperature
(Tornatzky and Miczek, 1993; Sgoifo et al., 1999, 2002; Meerlo
et al., 2002) and maladaptive cardiac hypertrophy (Gelsema et al.,
1994). Seven brief exposures to social defeat increased the LF/HF
ratio at rest, indicating a shift of sympathovagal balance toward a
relative prevalence of sympatheticmodulation (Wood et al., 2012).
These ﬁndings were extended in a recent report where as few
as four brief exposures to social defeat produced chronic reduc-
tions in both HRV and cardiac baroreﬂex sensitivity, reﬂecting
a shift toward sympathetic predominance (Sevoz-Couche et al.,
2013) which have been shown to be predictive of the occurrence
of life threatening arrhythmias (Billman et al., 1982; La Rovere
et al., 2003). Similarly, in prairie voles social isolation reduces
resting HRV, increases cardiac weight and increases suscepti-
bility to forced swim-induced arrhythmias (Grippo et al., 2007,
2012). Dysfunction within both the HPA axis and the immune
system of socially stressed animals are also reported as persis-
tent outcomes and mimic maladaptive changes seen in people
with psychiatric diseases (Stefanski, 1998; Buwalda et al., 1999;
Bhatnagar and Vining, 2003; Wood et al., 2010). Relevant long
lasting behavioral consequences include decreased motivation,
increased behavioral despair, anhedonia, anxiety-like behaviors,
and decreased social interactions (Von Frijtag et al., 2000; Rygula
et al., 2005; Grippo et al., 2007; Becker et al., 2008; Wohleb et al.,
2011; Patki et al., 2013). Taken together, these studies provide
evidence that repeated social defeat in rodents or chronic social
isolation in prairie voles possesses the unique ability to recapitulate
the behavioral and physiological changes associated with depres-
sive and anxiety disorders. Taken together, these social stressors
represent relevant models to study the comorbidity between psy-
chiatric disorders and CVD, shedding light on mechanisms and
biomarkers that may lead to increased susceptibility to psychiatric
disorders with comorbid autonomic dysfunction. The following
sections of this review report evidence from clinical and preclinical
social stress studies highlighting putative biomarkers that should
be further evaluated for their role in the pathogenesis of these
comorbid conditions.
PUTATIVE BIOMARKER INVOLVED IN PSYCHIATRIC-CVD
COMORBIDITY: CORTICOTROPIN-RELEASING FACTOR
There are several stress-sensitive biological molecules that have
both pro-depressive or anxiogenic effects and impact the auto-
nomic nervous system. As such, these molecules are classiﬁed as
putative biomarkers driving the comorbidity between psychiatric
disorders and autonomic dysfunction. One potential biomarker
is corticotropin-releasing factor (CRF). This neuropeptide is con-
sidered the “hallmark” of the stress response (Vale et al., 1981).
In stress-sensitive regions of the brain such as the amygdala,
locus coeruleus (LC) and dorsal raphe CRF receptor activation
is involved in stress-related emotionality and produces behavioral
features of the stress response (Heinrichs et al., 1992; Hammack
et al., 2003; Ayala et al., 2004; Wood and Woods, 2007; Dunn and
Swiergiel, 2008; Valentino et al., 2009). Central administration of
CRF in rats also activates the sympathetic nervous system, result-
ing in a marked pressor response and tachycardia (Briscoe et al.,
2000; Nijsen et al., 2000). CRF’s inﬂuence on the sympathovagal
balance also extends into the periphery; intravenous infusion of
CRF transiently increased the LF/HF ratio and tachycardia (Arlt
et al., 2003). Given CRF’s pervasive inﬂuence, it plays a central role
in the behavioral, neuroendocrine and cardiovascular limbs of the
stress response.
Like many elements of the stress response CRF is capable of
promoting healthy adaptation to stress (Vale et al., 1981), but
when unabated it can lead to pathology. For example, social
defeat and social isolation impacts CRF levels as well as CRF1
receptor distribution and quantity in brain and pituitary (Wood
et al., 2009, 2010, 2013; Pournajaﬁ-Nazarloo et al., 2011; Chaijale
et al., 2013). Moreover, transgenicmice engineered to over-express
CRF in the brain are disposed to exhibiting a depressive- and
anxiety-like phenotype as well as decreased HRV (Dirks et al.,
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2002; Vicentini et al., 2009; Bangasser et al., 2013). Overproduc-
tion of central CRF as evidenced by increased CRF has been
identiﬁed in CSF of patients with depressive disorders and anxi-
ety disorders such as PTSD (Nemeroff et al., 1984; Bremner et al.,
1997; Baker et al., 1999). In post mortem depressed patients,
speciﬁc changes in CRF within brain regions implicated in psy-
chiatric disorders are also documented. For example, increased
CRF protein levels have been documented in the LC and the par-
aventricular nucleus of the hypothalamus (Raadsheer et al., 1994;
Austin et al., 2003; Bissette et al., 2003). Furthermore, CRF recep-
tor mRNA down-regulation was reported in the frontal cortex
of depressed patients and was thought to be a secondary conse-
quence of exaggerated CRF release (Merali et al., 2004). Due to
the convincing link between CRF dysfunction and psychiatric dis-
orders, clinical trials have evaluated the therapeutic efﬁcacy of
CRF1 antagonists. While the results have been equivocal, there is
evidence to support their use as a promising new pharmacother-
apy for anxiety and depression (Holsboer and Ising, 2008). The
ambiguous nature of clinical results evaluating CRF1 antagonists
is suggested to be, in part, due to testing ineffective doses and
the wrong patient population (Belzung, 2014). Preclinical studies
have suggested that disorders with a high contribution of stress
in the etiology, such as PTSD and stress-induced depression, may
beneﬁt from CRF antagonists (Wood et al., 2012; Philbert et al.,
2013) however, individuals with stress-induced disorders were
not tested (Belzung, 2014). For example, CRF antagonist treat-
ment blocked depressive-like behavior following social isolation in
prairie voles (Bosch et al., 2009). Furthermore, our recent studies
revealed that social defeat-induced depressive-like behaviors, HPA
dysfunction and decreased HRV was blocked by a CRF1 antago-
nist during stress (Wood et al., 2010, 2012). Therefore, converging
lines of evidence underscore the role of CRF in the development
of stress-induced comorbidity between depression or anxiety and
CVD.
PUTATIVE BIOMARKER INVOLVED IN PSYCHIATRIC-CVD
COMORBIDITY: NEUROPEPTIDE Y
Neuropeptide Y (NPY) is yet another neuroendocrine peptide
that has demonstrated central control over both behavioral and
cardiovascular responses to stress. NPY is widely distributed in
the brain and expressed in regions implicated in psychiatric dis-
orders. NPY is often co-expressed with the neuropeptide CRF
and as such, it is poised to impact central regulation of stress-
related behavior, neuroendocrine and cardiovascular responses.
For example, the LC (Makino et al., 2000), the amygdala (Adrian
et al., 1983), and the PVN (Baker andHerkenham, 1995) all highly
express both neuropeptides and NPY is reported to oppose the
effects of CRF (Heilig et al., 1994; Britton et al., 2000). One such
example occurs in the LC, where CRF serves as an excitatory neu-
rotransmitter (Valentino et al., 1983) and NPY reduces the ﬁring
of LC noradrenergic neurons (Illes et al., 1993). As a result, cen-
tral administration of NPY decreases NE overﬂow by acting on
Y1 receptors (Hastings et al., 2004). Because evidence of elevated
LC activity has been linked to depression and PTSD (Wong et al.,
2000; Geracioti et al., 2001) this NPY-induced brake on LC over
activation may therefore promote stress resilience. The anti-stress
effect of NPY is not unique to the LC; decreased levels of NPY
were observed in the amygdala, hippocampus and periaqueductal
gray of rats that were vulnerable to predator-scent stress versus
the resilient phenotype (Cohen et al., 2012). Furthermore, social
defeat exposure decreases NPY and NPY receptor mRNA in the
hippocampus and hypothalamus (Zambello et al., 2010). Elevated
NPY levels have also been associated with resistance to an anx-
ious phenotype; in rats characterized as exhibiting high or low
levels of anxiety, NPY mRNA in the amygdala was negatively
correlated with anxious behavior (Primeaux et al., 2006). More-
over, central administration of exogenous NPY has demonstrated
anxiolytic properties in rodents and is capable of inhibiting the
anxiogenic effects of CRF (Britton et al., 1997; Ehlers et al., 1997;
Primeaux et al., 2005). Importantly, these preclinical data are rel-
evant to ﬁndings in humans; deﬁciencies within the central NPY
system have been demonstrated in patients with major depression
(Widerlov et al., 1988). Combat-exposed individuals with PTSD
also have signiﬁcantly lower levels of NPY in CSF (Rasmusson
et al., 2000; Sah et al., 2014) and NPY levels recover following
remission (Yehuda et al., 2006). Along these lines, high levels of
NPY were observed in highly resilient special operations soldiers
(Morgan et al., 2000). Therefore, clinical and preclinical data point
toward increased NPY promoting resilience, while reduced NPY
in the brain is related to psychiatric disorders.
In addition to its cognitive effects, NPY has prominent cardio-
vascular impact. Like NPY’s effect on anxiety, its hemodynamic
effects are also in contrast to CRF; central administration of NPY
lowers blood pressure and heart rate at rest and in response to
social defeat in rats (Klemfuss et al., 1998). The marked depressor
and bradycardic actions of NPY occur at doses that have potent
anxiolytic properties (Britton et al., 1997; Klemfuss et al., 1998).
However, while the central actions of NPY may be cardioprotec-
tive, peripheral NPY infusion in rodent and inman acts as a potent
vasoconstrictor (Pernow et al., 1987). NPY is co-released with NE
during conditions of high-intensity sympathetic nerve activity and
studies inmice lacking theNPY1 receptor revealed thatNPY serves
to potentiate NE-evoked vasoconstriction (Lundberg et al., 1986;
Pedrazzini et al., 1998). As such, peripheral NPY is associated
with CVD such as heart failure, hypertension and myocardial
ischemia (Zukowska-Grojec et al., 1996). Nonetheless, therapies
that increase NPY selectively in the brain may prove effective in
treating anxiety or depressive disorders and decrease cardiovas-
cular risk by reducing sympathetic activity. In rodents, the single
prolonged stress PTSDmodel produces many behavioral and bio-
chemical features of PTSD (Liberzon et al., 1997) and in a recent
study, intranasal NPY effectively blocked or reversed many of the
consequences of this stressor (Serova et al., 2013, 2014). Several
lines of evidence link NPY with the psychobiology of resilience
to psychiatric disorders and CVD comorbidity. Therefore, investi-
gating the efﬁcacy of intranasal NPY for PTSD and depression as
well as mitigating CVD risk in these patients will be critical.
PUTATIVE BIOMARKER INVOLVED IN PSYCHIATRIC-CVD
COMORBIDITY: INFLAMMATORY CYTOKINES
Proinﬂammatory cytokines are another such mediator that can
be persistently up regulated as a result of stress in vulnerable
individuals and has roots in the pathogenesis of both psychi-
atric disorders and CVD (Black and Garbutt, 2002). In fact,
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inﬂammation has long been recognized as contributing to CVD
and recently, converging evidence implicates inﬂammatory fac-
tors in the pathogenesis of depression and anxiety disorders.
Patients suffering from depression exhibit increased levels of the
proinﬂammatory cytokine interleukin-6 (IL-6) while at rest and
exhibit greater social stress-induced IL-6 levels, which are nor-
malized following antidepressant therapy (Frommberger et al.,
1997; Pace et al., 2006; Fagundes et al., 2013). Furthermore,
Inﬂiximab, a monoclonal antibody against tumor necrosis factor-
α (TNF-α), exhibited antidepressant efﬁcacy in a subset of
patients characterized by elevated plasma cytokines (Raison et al.,
2013). Elevated inﬂammation has also been identiﬁed in patients
with various anxiety disorders, including PTSD (Vogelzangs
et al., 2013; Newton et al., 2014). Interestingly, NPY has an
inhibitory inﬂuence on neuroinﬂammation, further supporting
the role of NPY in resilience (detailed review in Malva et al.,
2012). Preclinical data also support the role of inﬂammation
in depressive-like behaviors; IL-6 knockout mice demonstrate
decreased depressive-like behaviors (Chourbaji et al., 2006). In
addition to the unique capability of social defeat to produce
an anxiety- and depressive-like phenotype with cardiovascular
alterations as discussed above, it has been reported to pro-
duce persistent increases in the proinﬂammatory markers IL-6
and TNFα (Kinsey et al., 2008). Furthermore, microglia isolated
from the brains of socially defeated mice produced markedly
higher levels of the proinﬂammatory molecules IL-6, TNF-α, and
monocyte chemoattractant protein-1 in response to the endo-
toxin lipopolysaccharide compared with controls (Wohleb et al.,
2011). Importantly, antidepressants attenuate inﬂammation-
induced brain cytokine production, as well as depressive-like
symptoms, further supporting a role for neuroinﬂammation in
depressive disorders in humans (Castanon et al., 2001; Yirmiya
et al., 2001).
Proinﬂammatory cytokines also possess potent cardiovascu-
lar effects. For example, both central and peripheral infusion of
the proinﬂammatory cytokine interleukin-1β induces a pressor
response and tachycardia in rats (Kannan et al., 1996). In humans,
cytokines are also linked to the autonomic nervous system, as
reductions in HRV are associated with higher concentrations
of IL-6 and TNF-α (Gonzalez-Clemente et al., 2007; von Kanel
et al., 2008). A growing, yet still poorly understood body of evi-
dence points toward neuroinﬂammation in the psychopathology
of stress-related disorders and must be further characterized for
the impact anti-inﬂammatory therapies may have on mitigating
CVD risk in these patients (Dantzer et al., 2008; Maes et al., 2009;
Rawdin et al., 2013).
There is a large body of evidence to suggest that psychosocial
stress plays a prominent role in the etiology and progression of
certain CVDs and psychiatric disorders. As such, there is a strong
association between psychiatric disorders and increased cardiac
morbidity and mortality. This review highlights proinﬂammatory
cytokines, CRF, and NPY systems amongst those capable of gen-
erating both depressive or anxiety-like behaviors and reductions
in HRV, thereby increasing CVD risk. Targeting these systems in
preclinical social stress models and in psychiatric disorder patients
with evidence of decreasedHRVmay prove beneﬁcial and warrant
further evaluation.
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